期刊
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
卷 162, 期 -, 页码 82-90出版社
ELSEVIER
DOI: 10.1016/j.jpba.2018.09.021
关键词
Metabolomics; HPLC-ESI-QTOE-MS; Systemic sclerosis; Biomarker; Acylcarnitines; 2-arachidonoylglycerol
资金
- Innovative Medicines Initiative Joint Undertaking [115565]
- European Union
- European Federation of Pharmaceutical Industries and Associations (EFPIA) companies'
- Spanish Ministry of Economy and Competitiveness (MINECO)
- European Social Fund (FSE) [PTQ-13-06429]
- Spanish Ministry of Education, Culture and Sports (FPU) [14/03992]
Systemic Sclerosis (SSc) is a chronic autoimmune disease whose origin and pathogenesis are not yet well known. Recent studies are allowing a better definition of the disease. However, few studies have been performed based on metabolomics. In this way, this study aims to find altered metabolites in SSc patients in order to improve their diagnosis, prognosis and treatment. For that, 59 SSc patients and 28 healthy volunteers participated in this study. Urine and plasma samples were analysed by a fingerprinting metabolomic approach based on HPLC-ESI-QTOF-MS. We observed larger differences in urine than plasma metabolites. The main deregulated metabolic families in urine were acylcarnitines, acylglycines and metabolites derived from amino acids, specifically from proline, histidine and glutamine. These results indicate perturbations in fatty acid beta oxidation and amino acid pathways in scleroderma patients. On the other hand, the main plasma biomarker candidate was 2-arachidonoylglycerol, which is involved in the endocannabinoid system with potential implications in the induction and propagation of systemic sclerosis and autoimmunity. (C) 2018 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据